AutoCyte's Neopath Acquisition Combines Automated Cytology Offerings
This article was originally published in The Gray Sheet
Executive Summary
AutoCyte is hoping that its acquisition of NeoPath, a stock-swap transaction valued at over $100 mil., will result in a 50% share of the U.S. Pap smear market.